Trudie Lobban MBE (CEO and Trustee, A-A, AF Association & STARS) talks about the impact of COVID-19 on AF detection in the community, and the importance of seeking advice for people who notice an irregular heartbeat.
Trudie Lobban MBE is CEO and Trustee at A-A, AF Association & STARS and has no financial disclosures in relation to this video.
Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Trudie Lobban, MBE, FRCP (Edin), Winter 2020.
Trending Topic
Atrial fibrillation (AF) remains a major clinical challenge in Europe, with ongoing needs for greater precision, safety, and long-term durability in ablation. The recent CE Mark approval of the TactiFlex™ Duo Ablation Catheter, combining high-resolution mapping with emerging pulsed-field ablation (PFA) technology, offers a new option to help address these gaps. Dr John Silberbauer explores how the device may enhance AF treatment, reviews the supporting clinical evidence, and considers what this milestone means for physicians and patients across Europe.
The challenges of improving risk prediction in atrial fibrillation were brought to the forefront through recent research on multiple biomarkers. This work explores how various biomarkers are linked to different outcomes and their potential to refine risk prediction. Early findings suggest that no single pathway is responsible for the observed outcomes, underscoring the need for larger, more comprehensive studies. Such studies must include a wide range of biomarkers and phenotypic associations to accurately determine and predict the diverse outcomes in patients with atrial fibrillation.
The COP-AF trial looked at the use of anti-inflammatory colchicine in patients undergoing major noncardiac thoracic surgery and reducing risk of cardiovascular complications, especially perioperative atrial fibrillation and myocardial injury after noncardiac surgery (MINS). We spoke to Prof. David Conen (...
It’s World Heart Rhythm Week 2023! Learn about key considerations for managing and treating arrhythmias, ongoing research and the importance of seeking medical advice for syncope.
The AdaptResponse trial was designed to assess two methods of restoring resynchronization to the heart in patients with heart failure with left bundle branch block. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) ...
Cardiac resynchronization therapy is designed to restore the electrical activation in a more natural way in patients with heart failure. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) to discuss the treatment paradigm ...
Recently it has been shown that NT-proBNP may be a useful tool for finding people with an increased risk of atrial fibrillation and stroke. In this touchCARDIO interview, we speak with Dr Søren Zöga Diederichsen (Copenhagen University Hospital, ...
The STROKESTOP and the LOOP studies have assessed the use of atrial fibrillation screening compared with usual care. In this touchCARDIO interview, we speak with Dr Søren Zöga Diederichsen (Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark) to discuss the ...
The POTTER AF registry looked at oesophageal fistula formation following atrial fibrillation ablation, with focus on the real world incidence, characteristics, optimal management and patient outcomes. In this touchCARDIO interview, we speak with Professor Roland Tilz (University Heart Center Lü...
Oesophageal fistula formation is a very rare complication following atrial fibrillation ablation with a very high mortality rate. In this touchCARDIO interview, we speak with Professor Roland Tilz (University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany) to ...
CEASE-AF is a trial comparing the efficacy and safety of hybrid total thoracoscopic ablation therapy to standard catheter ablation in patients with long standing persistent atrial fibrillation. In this touchCARDIO interview, we speak with Dr Nicolas Doll (Schuechtermann-Clinic, Bad Rothenfelde, ...
Complex 3D mappings indicated a need for an endocardial and epicardial approach to treat patients with a long standing persistent form of atrial fibrillation. In this touchCARDIO interview, we speak with Dr Nicolas Doll (Schuechtermann-Clinic, Bad Rothenfelde, Germany) to discuss ...
The AMALFI trial aims to assess the efficacy and cost effectiveness of an ECG patch to monitor for atrial fibrillation. In this touchCARDIO interview, we speak with Dr Rohan Wijesurendra (University of Oxford, Oxford, UK) to discuss the design of ...
Keep track of your clinical interests and newsletter subscriptions.
Or use a .
Already registered? Login below.
